New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.
New Guidance on Mental Health Screening in Pediatric Rheumatology
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
Benefits of Early Initiation of Biologic DMARDs in pJIA
The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
Belimumab Promising for Children with Lupus Nephritis
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…
Trends in the Use of DMARDs for Patients with JIA
Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.
ACR Image Competition 2024 Results, Part 4
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from the Middle East and North Africa. Lipoma Arborescens Revealed A 10-year-old boy, presented with a five-year history…
Youthful Exuberance: The Year in Review for Pediatric Rheumatology
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
Weathering the Cytokine Storm: Macrophage Activation Syndrome in Adults & Children
Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.
FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
- 1
- 2
- 3
- …
- 13
- Next Page »